Literature DB >> 399151

The production and characteristics of anti-insulin, anti-A-component and anti-proinsulin antibodies in patients treated with monocomponent or conventional insulin.

S Kawazu, Y Kanazawa, E Miki, M Hayashi, H Sando, H Kajinuma, Y Iwamoto, Y Akanuma, K Kosaka.   

Abstract

Highly purified pork monocomponent insulin produced less anti-insulin antibody than conventional insulins in diabetic patients. The smaller amount of anti-insulin antibody produced by MC insulin bound pork insulin more strongly than beef insulin in both displacement and direct binding studies of 125I-insulin. On the contrary, anti-insulin antibody which was produced by conventional insulins (beef insulin or mixture of pork and beef insulin) bound beef insulin more strongly. No significant anti-a-component and anti-proinsulin antibodies were detected in diabetics treated with highly purified monocomponent pork insulin about two years, compared to significant production of these antibodies in diabetics treated with conventional insulins. These results suggest that the species difference of the insulin molecule itself plays a significant role for the production of anti-insulin antibody, as the impurities do, in insulin-treated diabetic patients. The production of anti-insulin and anti-a-component antibodies decreased clearly after switching to highly purified monocomponent from conventional insulin. No effect of the switching on insulin requirement was found; however, better control of diabetes was accomplished in relation to the level of fasting blood sugar.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 399151     DOI: 10.1007/bf02587655

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  19 in total

1.  PRODUCTION OF AUTOANTIBODIES TO INSULIN IN MAN AND RABBITS.

Authors:  G M GRODSKY
Journal:  Diabetes       Date:  1965-07       Impact factor: 9.461

2.  Quantitative aspects of the reaction between insulin and insulin-binding antibody.

Authors:  S A BERSON; R S YALOW
Journal:  J Clin Invest       Date:  1959-11       Impact factor: 14.808

3.  Preparation of iodine-131 labelled human growth hormone of high specific activity.

Authors:  W M HUNTER; F C GREENWOOD
Journal:  Nature       Date:  1962-05-05       Impact factor: 49.962

4.  A method for the determination of plasma insulin antibodies and its application in normal and diabetic subjects.

Authors:  M Sebriakova; J A Little
Journal:  Diabetes       Date:  1973-01       Impact factor: 9.461

5.  [Experiences with monocomponent insulin treatment].

Authors:  W Korp; R E Levett
Journal:  Wien Klin Wochenschr       Date:  1973-05-04       Impact factor: 1.704

6.  Clinical aspects of insulin--antigenicity.

Authors:  J Schlichtkrull; J Brange; A H Christiansen; O Hallund; L G Heding; K H Jorgensen
Journal:  Diabetes       Date:  1972       Impact factor: 9.461

7.  Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays.

Authors:  B Desbuquois; G D Aurbach
Journal:  J Clin Endocrinol Metab       Date:  1971-11       Impact factor: 5.958

Review 8.  New forms of insulin and their use in the treatment of diabetes.

Authors:  D K Yue; J R Turtle
Journal:  Diabetes       Date:  1977-04       Impact factor: 9.461

9.  Immunological response to the prolonged administration of heterologous and homologous insulin in cattle.

Authors:  A E Renold; J Steinke; J S Soeldner; H N Antoniades; R E Smith
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

10.  Proinsulin and A-component antibodies in diabetics after long-term monocomponent insulin treatment.

Authors:  B Bruni; S Gamba; G Regis; G L Turco
Journal:  Diabetologia       Date:  1978-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.